| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/18/2002 | CN1369276A Composition and method for effectively losing body weight |
| 09/17/2002 | US6451992 Antithrombin activity; veterinary vaccines |
| 09/17/2002 | US6451982 Polypeptide with amino acid sequences grafted into human heavy and light chain variable regions |
| 09/17/2002 | US6451981 Inhibitor of cellular adhesion, migration or infiltration into areas of tissue damage, injury, or transplant |
| 09/17/2002 | US6451971 Polypeptide cell adhesion inhibitors; antimetastasis and anticarcinogenic agents |
| 09/17/2002 | US6451840 Regulation of T cell-mediated immunity by tryptophan |
| 09/17/2002 | US6451770 A liquid jet intradermal administration apparatus that administers an immunogenic composition or vaccine to an animal: without a needle, and into the epidermis, dermis and/or hypodermis; wherein the apparatus includes an |
| 09/17/2002 | US6451769 Compositions and methods for administering Borrelia DNA |
| 09/17/2002 | US6451605 Anise, calendula, quassia, rosemary, or sassafras volatile oil; alcohol and fatty ester emollient; lice insecticide |
| 09/17/2002 | US6451592 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| 09/17/2002 | US6451578 Hepatitis, amino acid sequences and nucleic acids |
| 09/17/2002 | US6451575 The invention is directed to the family of aggrecan degrading metallo proteases (admps) that exhibit the ability to cleave the aggrecan core protein between amino acid residues glu.sup.373 -ala.sup.374. the invention encompasses the |
| 09/17/2002 | US6451541 Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc |
| 09/17/2002 | US6451522 Combining agent to be tested, antibody or antigen-binding fragment which binds to amino terminal domain of mammalian cc-chemokine receptor 2, mammalian cc-chemokine receptor 2 or ligand-binding variant, measuring binding |
| 09/17/2002 | US6451338 Controlling particle size; foring liposomes, freeze drying, rehydration |
| 09/17/2002 | US6451325 Vaccines; oil in water emulsion and detergent; lipophilic muramyl dipeptide immunostimulant; free of ethylene oxide-propylene oxide block copolymer |
| 09/17/2002 | US6451323 Recombinant newcastle disease virus RNA expression systems and vaccines |
| 09/17/2002 | US6451322 Retrovirus like particles made non infectious by a plurality of mutations |
| 09/17/2002 | US6451321 Bird and poultry vaccine; side effect reduction of lesions |
| 09/17/2002 | US6451320 Combined hepatitis and herpesvirus antigen compositions |
| 09/17/2002 | US6451317 Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide |
| 09/17/2002 | US6451316 Incubating t-cells and antigen presenting cells in vitro with purified complex of heat shock protein and antigen; generating cd4 cells; immunotherapy, anticarcinogenic agents |
| 09/17/2002 | US6451315 Compounds and methods for the diagnosis and treatment of B. microti infection |
| 09/17/2002 | US6451314 MHC conjugates useful in ameliorating autoimmunity |
| 09/17/2002 | US6451313 Heterotetramer; expression vectors encoding heavy and light chains; viricides |
| 09/17/2002 | US6451311 An antibody which binds procalcitonin but not free calcitonin, free katacalcin and free n-procalcitonin; used as an in vitro or in vivo diagnostic agent |
| 09/17/2002 | US6451310 Preventing t cell activation of b cells by administering antibody cabable of binding protein recognized by monoclonal antibody 5c8 |
| 09/17/2002 | US6451307 3′-exonuclease, production and use thereof |
| 09/17/2002 | US6451305 Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand |
| 09/17/2002 | US6451286 Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
| 09/17/2002 | US6451284 Antibodies which target lymphoma cells which have a tendency to localize to the bone marrow. |
| 09/17/2002 | CA2260007C Method for treating gastrointestinal damage |
| 09/17/2002 | CA2243459C Human antibodies that bind human tnf.alpha. |
| 09/17/2002 | CA2238640C Non-toxic mutants of pathogenic gram-negative bacteria |
| 09/17/2002 | CA2221129C An improved peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone lhrh, and analogs of the lhrh tandem repeat peptide and their use as vaccine |
| 09/17/2002 | CA2187908C Non-splicing variants of gp350/220 |
| 09/17/2002 | CA2172989C Conotoxin peptides |
| 09/17/2002 | CA2111853C Substantially pure receptor like tgf-.beta.1 binding molecules and uses thereof |
| 09/17/2002 | CA2095534C Avirulent microbes and uses therefor |
| 09/17/2002 | CA2067919C Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them |
| 09/17/2002 | CA2047244C Genetically engineered immunoglobulins |
| 09/15/2002 | CA2373454A1 Recombinant infectious laryngotracheitis virus vaccine |
| 09/13/2002 | CA2374027A1 Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| 09/12/2002 | WO2002070748A2 Response of dendritic cells to a diverse set of pathogens |
| 09/12/2002 | WO2002070716A1 Allergen ole e 9 from olea europaea, recombinant dna coding for said allergen, the production and use thereof |
| 09/12/2002 | WO2002070711A1 Vaccine |
| 09/12/2002 | WO2002070708A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 09/12/2002 | WO2002070706A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | WO2002070695A2 Tumor associated proteins |
| 09/12/2002 | WO2002070679A2 Peptide fragments, derived from human telomerase reverse transcriptase |
| 09/12/2002 | WO2002070676A2 Use of protein histidine phosphatase |
| 09/12/2002 | WO2002070669A2 Secreted proteins |
| 09/12/2002 | WO2002070665A2 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 09/12/2002 | WO2002070657A2 93870, a human g-protein coupled receptor and uses therefor |
| 09/12/2002 | WO2002070563A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070562A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070561A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070560A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070559A2 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | WO2002070558A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070557A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070556A1 POLYPEPTIDE OF A P53 PROTEIN-SPECIFIC MURINE Α/β T-CELL RECEPTOR, NUCLEIC ACIDS CODING THEREFOR AND USE THEREOF |
| 09/12/2002 | WO2002070553A1 Tumour peptide antigen produced from human mdm2 proto-oncogene |
| 09/12/2002 | WO2002070552A2 POLYPEPTIDE FROM A HDM2 PROTEIN SPECIFIC MURINE Α/β T-CELL RECEPTORS, NUCLEIC ACIDS CODING FOR THE ABOVE AND USE THEREOF |
| 09/12/2002 | WO2002070542A2 Band 3 antigenic peptides, malaria polypeptides and uses thereof |
| 09/12/2002 | WO2002070010A1 Graft rejection inhibitors |
| 09/12/2002 | WO2002070008A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | WO2002070007A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 09/12/2002 | WO2002070006A2 Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| 09/12/2002 | WO2002070005A1 Compositions of multimeric profilin for diagnosis and treatment of allergies |
| 09/12/2002 | WO2002070004A2 Papillomavirus vaccines |
| 09/12/2002 | WO2002070003A1 Altered peptide ligands |
| 09/12/2002 | WO2002070001A2 Use of lp82 to treat hematopoietic disorders |
| 09/12/2002 | WO2002069985A2 Immune response potentiation |
| 09/12/2002 | WO2002069908A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 09/12/2002 | WO2002069907A2 Anti-neovasculature preparations for cancer |
| 09/12/2002 | WO2002069904A2 Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| 09/12/2002 | WO2002069886A2 Modified proteins, designer toxins, and methods of making thereof |
| 09/12/2002 | WO2002069840A2 Nucleic acids for transforming fish cells and methods for their use |
| 09/12/2002 | WO2002069799A1 Method of predicting stroke evolution utilising mri |
| 09/12/2002 | WO2002069691A2 Immunogenic hiv peptides for use as reagents and vaccines |
| 09/12/2002 | WO2002063010A9 Method of producing recombinant antibodies against tumors |
| 09/12/2002 | WO2002062851A8 Conformationally abnormal forms of tau proteins and specific antibodies thereto |
| 09/12/2002 | WO2002053178A3 Immunogenic complex comprising ribosomes |
| 09/12/2002 | WO2002053175A3 Use of botulinum toxin for treatment of articular pathologies |
| 09/12/2002 | WO2002051865A3 Proteinic antigens inducing antibodies neutralising hiv virus |
| 09/12/2002 | WO2002047703A3 Immune system stimulation |
| 09/12/2002 | WO2002022680A3 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 09/12/2002 | WO2002016410A3 Peptide selection method |
| 09/12/2002 | WO2002014369A3 Human kininogen d5 domain polypeptides and their use |
| 09/12/2002 | WO2001083529A3 Immunoadhesin for the prevention of rhinovirus infection |
| 09/12/2002 | WO2001077335A3 Listeria monocytogenes genome, polypeptides and uses |
| 09/12/2002 | WO2001041797A9 Systemic immune response induced by mucosal administration of l ipid-tailed polypeptides without adjuvant |
| 09/12/2002 | WO2001036626A9 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 09/12/2002 | WO2001035811A3 Methods of diagnosing and determining prognosis of breast cancer |
| 09/12/2002 | WO2001035102A3 Diagnosis and treatment of malignant neoplasms |
| 09/12/2002 | WO2001030848A3 Nucleic acids of the human abc1 gene and applications thereof |
| 09/12/2002 | WO2001016183A9 Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
| 09/12/2002 | WO2001015694A9 Extended duration light activated cancer therapy |
| 09/12/2002 | WO2001010901A9 Antimicrobial histone h1 compositions, kits, and methods of use thereof |